Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo

<p>Abstract</p> <p>Background</p> <p>Using gene expression profiling, we previously identified CDC25B to be significantly highly expressed in hepatocellular carcinoma (HCC) compared to non-tumor liver. CDC25B is a cell cycle-activating phosphatase that positively regula...

Full description

Bibliographic Details
Main Authors: He Jing, Chua Mei-Sze, Yan Xinrui, So Samuel K
Format: Article
Language:English
Published: BMC 2008-02-01
Series:Molecular Cancer
Online Access:http://www.molecular-cancer.com/content/7/1/19
_version_ 1818915433319759872
author He Jing
Chua Mei-Sze
Yan Xinrui
So Samuel K
author_facet He Jing
Chua Mei-Sze
Yan Xinrui
So Samuel K
author_sort He Jing
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Using gene expression profiling, we previously identified CDC25B to be significantly highly expressed in hepatocellular carcinoma (HCC) compared to non-tumor liver. CDC25B is a cell cycle-activating phosphatase that positively regulates the activity of cyclin-dependent kinases, and is over-expressed in a variety of human malignancies. In this study, we validated the over-expression of CDC25B in HCC, and further investigated its potential as a therapeutic target for the management of HCC.</p> <p>Results</p> <p>Quantitative real-time polymerase chain reaction and immunohistochemical staining of patient samples confirmed the significant over-expression of CDC25B in HCC compared to non-tumor liver samples (<it>P </it>< 0.001). Thus, intefering with the expression and activity of CDC25B may be a potential way to intervene with HCC progression. We used RNA interference to study the biological effects of silencing CDC25B expression in HCC cell lines (Hep3B and Hep40), in order to validate its potential as a therapeutic target. Using small oligo siRNAs targeting the coding region of CDC25B, we effectively suppressed CDC25B expression by up to 90%. This was associatetd with significant reductions in cell growth rate, cell migration and invasion through the matrigel membrane, and caused significant cell cycle delay at the G2 phase. Finally, suppression of CDC25B significantly slowed the growth of Hep40 xenografts in nude mice.</p> <p>Conclusion</p> <p>Our data provide evidence that the inhibition of CDC25B expression and activity lead to suppression of tumor cell growth and motility, and may therefore be a feasible approach in the clinical management of HCC.</p>
first_indexed 2024-12-20T00:02:12Z
format Article
id doaj.art-53f6fb845b3441cab16614ce11caa571
institution Directory Open Access Journal
issn 1476-4598
language English
last_indexed 2024-12-20T00:02:12Z
publishDate 2008-02-01
publisher BMC
record_format Article
series Molecular Cancer
spelling doaj.art-53f6fb845b3441cab16614ce11caa5712022-12-21T20:00:48ZengBMCMolecular Cancer1476-45982008-02-01711910.1186/1476-4598-7-19Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivoHe JingChua Mei-SzeYan XinruiSo Samuel K<p>Abstract</p> <p>Background</p> <p>Using gene expression profiling, we previously identified CDC25B to be significantly highly expressed in hepatocellular carcinoma (HCC) compared to non-tumor liver. CDC25B is a cell cycle-activating phosphatase that positively regulates the activity of cyclin-dependent kinases, and is over-expressed in a variety of human malignancies. In this study, we validated the over-expression of CDC25B in HCC, and further investigated its potential as a therapeutic target for the management of HCC.</p> <p>Results</p> <p>Quantitative real-time polymerase chain reaction and immunohistochemical staining of patient samples confirmed the significant over-expression of CDC25B in HCC compared to non-tumor liver samples (<it>P </it>< 0.001). Thus, intefering with the expression and activity of CDC25B may be a potential way to intervene with HCC progression. We used RNA interference to study the biological effects of silencing CDC25B expression in HCC cell lines (Hep3B and Hep40), in order to validate its potential as a therapeutic target. Using small oligo siRNAs targeting the coding region of CDC25B, we effectively suppressed CDC25B expression by up to 90%. This was associatetd with significant reductions in cell growth rate, cell migration and invasion through the matrigel membrane, and caused significant cell cycle delay at the G2 phase. Finally, suppression of CDC25B significantly slowed the growth of Hep40 xenografts in nude mice.</p> <p>Conclusion</p> <p>Our data provide evidence that the inhibition of CDC25B expression and activity lead to suppression of tumor cell growth and motility, and may therefore be a feasible approach in the clinical management of HCC.</p>http://www.molecular-cancer.com/content/7/1/19
spellingShingle He Jing
Chua Mei-Sze
Yan Xinrui
So Samuel K
Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
Molecular Cancer
title Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
title_full Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
title_fullStr Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
title_full_unstemmed Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
title_short Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo
title_sort small interfering rna targeting cdc25b inhibits liver tumor growth in vitro and in vivo
url http://www.molecular-cancer.com/content/7/1/19
work_keys_str_mv AT hejing smallinterferingrnatargetingcdc25binhibitslivertumorgrowthinvitroandinvivo
AT chuameisze smallinterferingrnatargetingcdc25binhibitslivertumorgrowthinvitroandinvivo
AT yanxinrui smallinterferingrnatargetingcdc25binhibitslivertumorgrowthinvitroandinvivo
AT sosamuelk smallinterferingrnatargetingcdc25binhibitslivertumorgrowthinvitroandinvivo